With demonstrated noninferiority to TAP, TC is the global first-line standard for advanced endometrial cancer.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: